TY  -  JOUR
AU  -  Valsecchi, Paolo
AU  -  Garozzo, Andrea
AU  -  Nibbio, Gabriele
AU  -  Barlati, Stefano
AU  -  Deste, Giacomo
AU  -  Turrina, Cesare
AU  -  Sacchetti, Emilio
AU  -  Vita, Antonio
T1  -  Paliperidone extended-release in the short- and long-term treatment of schizophrenia
PY  -  2019
Y1  -  2019-03-01
DO  -  10.1708/3142.31245
JO  -  Rivista di Psichiatria
JA  -  Riv Psichiatr
VL  -  54
IS  -  2
SP  -  43
EP  -  58
PB  -  Il Pensiero Scientifico Editore
SN  -  2038-2502
Y2  -  2026/05/04
UR  -  http://dx.doi.org/10.1708/3142.31245
N2  -  SUMMARY. Paliperidone is a second-generation antipsychotic drug belonging to the class of benzisoxasole derivatives. Paliperidone is the major active metabolite of risperidone (9-OH-risperidone) and, as such, is comparable to the latter in terms of pharmacodynamic properties. However, due to its peculiar characteristics, paliperidone may be particularly useful in the treatment of schizophrenic patients. In this critical review of the literature the efficacy and tolerability in the short- and in the long-term have been evaluated in patients with schizophrenia. Taking into account the tolerability and efficacy data, together with the use of innovative sustained-release formulation, with a peculiar pharmacokinetic profile that allows single daily administration, paliperidone can be considered a valid option both for the short and the long-term treatment of schizophrenia.
ER  -